Merck (MRK) earnings report Q2 2025

Lens On Tuesday, he said he would get back the costs of $ 3 billion by the end of 2027 to support new product launch and drug pipeline.

Multi -year effort, Merck’s cancer drug records in 2028, Keytruda’nın income losses caused by the end of the patent of the future patent, while President Donald Trump’s planned tariffs on the pharmaceuticals imported to the United States to support Merck and other companies in the United States.

Merck CEO Rob Davis said in the next version, “Today, we have announced a perennial optimization attempt to direct the transformation of our portfolio from more mature areas to our new growth drivers, to enable our portfolio, and to direct our productive, innovation -oriented growth department.” He said.

As part of efforts, Merck approved a new restructuring program in July that will eliminate certain administrative, sales and research and development positions. However, the company will continue to hire employees in new roles in the growth areas of the business. Merck will also reduce the global real estate footprint and will continue to take back the production network.

Merck expects to produce about $ 1.7 billion in annual cost savings, most of which will begin until the end of 2027.

The company expects pre -tax costs for the restructuring program to have a total of approximately 3 billion dollars. Merck for the second quarter, the program for a fee of $ 649 million.

On Tuesday, Merck reported the second quarter income under Wall Street forecasts. Metric had missed expectations for the first time since April 2021.

While Keytruda sales grew during the period, Merck continued to see Gardasil’s problems with Chinese sales, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the USA.

In February, Merck announced his decision to stop the sending of Gardasil to China from that month and pass at least in the middle of 2025. Merck Cfo Caroline Litchfield, in a statements prepared on Tuesday, said the company would not continue posts to China until the end of 2025, and that the stocks remained high and that the demand is still soft.

The company also narrowed the full -year guidance. Merck now expects 2025 corrected earnings to be between 8.87 and $ 8,97 per share. This is compared to the previous view of $ 8.82 to $ 8.97 per share.

Merck expects the income for the year to arrive between $ 64.3 billion and $ 65.3 billion, narrowed at both ends from the previous guidance of $ 64.1 billion to $ 65.6 billion.

Based on a questionnaire of LSEG’s analysts, what is reporting is explained below when Merck’s Wall Street expects for the second quarter:

• Earning per share: $ 2,13 set. This figure may not be compared with estimates of $ 2.01.
• Revenues: 15.81 billion dollars and 15.89 billion dollars expected

Merck said that guidance contains an estimated $ 200 million estimated effect on Trump’s tariffs so far. In April, the company said that the expected tariff fee first reflects the taxes between the US and China, but did not explain the sector -specific pharmaceutical tariffs.

The appearance also includes one -time fees for the company’s license agreements with Hengrui Pharma and Lanova, but not recently the purchase of Verona Pharma.

The company recorded a net income for a quarter of 4.43 billion dollars or $ 1.76 per share. This is compared to $ 5.46 billion or $ 2.14 per share with net income during the age of the year.

Excluding acquisition and restructuring costs, Merck won $ 2.13 per share in the second quarter. This includes 7 cents per share to close the license agreement with Hengrui Pharma.

Merck fell by 2% compared to the same period of the previous year and earned 15.81 billion dollars for the quarter.